i-manager Publications

Advertising and Marketing within the Pharmaceutical industry: Navigating ethical and regulatory-demanding situations

Rehan Haider*, Anjum Zehra**, Asghar Mehdi***, Geetha Kumari Das****, Zameer Ahmed*****, Sambreen Zameer******

* Department of Pharmacy, University of Karachi.

** Department of Microbiology, University of Karachi, Pakistan.

*** Department of Pharmacology, Fazaia Ruth Pfau Medical College, Air University, Karachi.

**** GD Pharmaceutical Inc, OPJS University, Rajasthan.

***** Dow University of Health Sciences, Karachi, Pakistan.

****** Department of Pathology, Dow University of Health Sciences, Karachi, Pakistan.

Periodicity:January - June'2024

Abstract

Marketing and advertising are crucial in pharmaceutical manufacturing, showcasing key finishes and disseminating information about drugs, conditions, and healthcare products to professionals and consumers. However, these activities face strict regulations and ethical concerns due to their significant impact on public health and safety. This paper examines the complex landscape of broadcasting and advertising in the pharmaceutical industry, focusing on the ethical and regulatory challenges faced by industry stakeholders. It begins with an overview of the fundamental laws governing drug billing and advertising, emphasizing the importance of honesty, transparency, and integrity in all marketing efforts. The paper then explores the regulatory framework overseeing drug promotion and sales, highlighting key guidelines set by bodies such as the FDA in the U.S. and the EMA in Europe. These regulations cover various aspects of drug marketing, including content requirements, risk and side effect disclosures, and interactions with healthcare professionals (Bailey, 2001). The paper discusses the impact of mathematical and public television rules, direct-toconsumer advertising, and personalized shopping trends. It argues that ethical issues shape drug marketing strategies, addressing overpromotion, misleading claims, and potential conflicts of interest. By examining the ethical and regulatory landscape, the paper provides insights into best practices for drug advertising, emphasizing compliance with regulations, adherence to ethical standards, and the commitment to providing balanced and accurate information to ensure the safe and effective use of pharmaceuticals.

Keywords

Marketing, Advertising, Pharmaceutical Industry, Regulatory Compliance, Ethical Consideration, Drug Promotion, Healthcare Products, Consumer Safety.

How to Cite this Article?

Haider, R., Zehra, A., Mehdi, A., Das, G. K., Ahmed, Z., and Zameer, S. (2024). Advertising and Marketing within the Pharmaceutical Industry: Navigating Ethical and Regulatory-Demanding Situations. Dale View's Journal of Clinical Pharmacology and Pharmacotherapeutics, 1(1), 28-40.

References

[1]. Association of the British Pharmaceutical Industry. (2024). Value and Access, Manufacturing, Working in Partnership, Health Data, Trade and IP.

[2]. Australian Academy of Science. (1995). Submission to the Industry Commission Asking into the Drug Manufacturing.

[3]. Bailey, M. (2001). Priced Out of Reach: How WTO Patent Policies Will Reduce Access to Medicines in the Developing World. Oxfam International.

[4]. Boltri, J. M., Gordon, E. R., & Vogel, R. L. (2002). Effect of antihypertensive samples on physician prescribing patterns. Family Medicine, 34(10), 729-731.

[5]. European Commission. (2000). Pharmaceuticals in the European Union.

[6]. European Parliamentary Research Service. (2021). European Pharmaceutical Research and Development.

[7]. Food and Drug Administration. (1999). Consumer- Directed Broadcast Advertisements.

[8]. Gaedeke, R. M., Tootelian, D. H., & Sanders, E. E. (1999). Value of services provided by pharmaceutical companies: Perceptions of physicians and pharmaceutical sales representatives. Health Marketing Quarterly, 17(1), 23-31.

[9]. Hodges, B. (1995). Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks. Canadian Medical Association Journal (CMAJ), 153(5), 553.

[10]. Joint Formulary Committee (Ed.). (2012). British National Formulary. Pharmaceutical Press.

[11]. Jones, M., Greenfield, S., & Bradley, C. (1999). A survey of the advertising of nine new drugs in the general practice literature. Journal of Clinical Pharmacy and Therapeutics, 24(6), 451-460.

[12]. Kanavos, P., & Gemmill, M. (2005). Pharmaceutical Pricing and Reimbursement in Europe. Scrip.

[13]. Martikainen, J., & Rajaniemi, S. (2002). Drug Reimbursement Systems in EU Meember States, Iceland and Norway. Social Insurance Institution, Helsinki.

[14]. Masood, I., Ibrahim, M., Hassali, M., & Ahmed, M. (2009). Evolution of marketing techniques, adoption in pharmaceutical industry and related issues: a review. Journal of Clinical and Diagnostic Research, 3(6), 1942- 1952.

[15]. Matthews M. (2001). Who's Afraid of Pharmaceutical Advertising?

[16]. Mullin, R. (2004). As high-throughput screening draws fire, researchers leverage science to put automation into perspective. Chemical & Engineering News, 82, 23-32.

[17]. Nolan, A. (2000). Pharmaceutical advertising in clinical software. Australian Prescriber, 23(3), 52.

[18]. Palumbo, F. B., & Mullins, C. D. (2002). The development of direct-to-consumer prescription drug advertising regulation. Food & Drug LJ, 57, 423.

[19]. PMLiVE. (n.d.). Pharmaceutica Marketing Live.

[20]. Prosser, H., & Walley, T. (2003). Understanding why GPs see pharmaceutical representatives: A qualitative interview study. British Journal of General Practice, 53(489), 305-311.

[21]. Rados, C. (2004). Truth in advertising: Rx drug ads come of age. FDA Consumer, 38(4), 20-27.

[22]. Rahman, M., Rodríguez-Serrano, M. Á., & Lambkin, M. (2020). Advertising efficiency and profitability: evidence from the pharmaceutical industry. Industrial Marketing Management, 89, 619-629.

[23]. Robinson, A. R., Hohmann, K. B., Rifkin, J. I., Topp, D., Gilroy, C. M., Pickard, J. A., & Anderson, R. J. (2004). Direct-to-consumer pharmaceutical advertising: Physician and public opinion and potential effects on the physician-patient relationship. Archives of Internal Medicine, 164(4), 427-432.

[24]. Steinman, M. A., Shlipak, M. G., & McPhee, S. J. (2001). Of principles and pens: Attitudes and practices of medicine housestaff toward pharmaceutical industry promotions. The American Journal of Medicine, 110(7), 551-557.

[25]. Villanueva, P., Peiró, S., Librero, J., & Pereiró, I. (2003). Accuracy of pharmaceutical advertisements in medical journals. The Lancet, 361(9351), 27-32.

[26]. Vitry, A. (2004). Is Australia free from direct-to- customer advertising?. Australian Prescriber, 27(1), 4-6.

[27]. Vogenberg, F. R. (2003). Costs of Pharmacy Care and Issues of Drug Utilization. P AND T, 28(7), 460-461.

[28]. World Health Organization. (2000). WHO Medicines Strategy 2000-2003. World Health Organization.

If you have access to this article please login to view the article or kindly login to purchase the article

Single Article

	North Americas,UK, Middle East,Europe		India	Rest of world
	USD	EUR	INR	USD-ROW
Pdf	300
Online	300
Pdf & Online	500

ADD TO CART

Options for accessing this content:

If you would like institutional access to this content, please recommend the title to your librarian.
If you already have i-manager's user account: Login above and proceed to purchase the article.
New Users: Please register, then proceed to purchase the article.